Aclaris starts phase 1b trial of ATI-052 for atopic dermatitis Jan 12, 2026 06:55AM
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052 Jan 12, 2026 06:55AM
Aclaris reports positive phase 1a results for ATI-052 bispecific antibody Jan 6, 2026 06:59AM
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development Jan 6, 2026 06:59AM
Aclaris Therapeutics added to NASDAQ Biotechnology Index Dec 19, 2025 04:01PM
View Older Stories

Dec 19, 2025 04:01PM Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)
Nov 25, 2025 08:00AM Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Nov 6, 2025 06:59AM Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Oct 29, 2025 07:30AM Aclaris Therapeutics to Participate in Three November Healthcare Conferences
Sep 30, 2025 07:00AM Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025
Sep 30, 2025 07:00AM Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025
Sep 9, 2025 07:00AM Aclaris to present ATI-2138 atopic dermatitis data at EADV congress
Sep 9, 2025 07:00AM Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress
Aug 27, 2025 08:00AM Aclaris Therapeutics to Participate in Two September Healthcare Conferences
Aug 7, 2025 06:59AM Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jul 29, 2025 04:02PM Aclaris reports positive Phase 2a results for atopic dermatitis drug
Jul 29, 2025 04:01PM Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Se
Jul 28, 2025 08:45AM Aclaris Therapeutics names Roland Kolbeck as chief scientific officer
Jul 28, 2025 08:45AM Aclaris Therapeutics Announces Leadership Transition
Jun 30, 2025 09:32AM Aclaris Therapeutics (ACRS) Added to the Russell 2000 and Russell 3000 Indexes
Jun 30, 2025 09:31AM Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes
Jun 26, 2025 04:01PM Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference
Jun 26, 2025 04:01PM Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference
Jun 23, 2025 06:59AM Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052
Jun 2, 2025 07:02AM Aclaris Therapeutics (ACRS) Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
Jun 2, 2025 06:59AM Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
May 28, 2025 09:20AM Aclaris Therapeutics to Participate in Two June Healthcare Conferences
May 9, 2025 07:00AM Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series
May 8, 2025 06:50AM Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Apr 29, 2025 07:02AM Aclaris Therapeutics (ACRS) Appoints Jesse Hall as Chief Medical Officer
Apr 29, 2025 07:00AM Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer
Apr 22, 2025 06:59AM Aclaris Therapeutics (ACRS) Secures U.S. Food and Drug Administration IND Clearance for ATI-052
Apr 22, 2025 06:59AM Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody
Mar 4, 2025 07:00AM Aclaris Therapeutics to Participate in Two March Healthcare Conferences
Feb 27, 2025 06:59AM Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
Dec 21, 2022 07:04AM Eric Gulve Announces Retirement as President of BioSTL Startup Arm BioGenerator; Charlie Bolten to Take the Helm
Aug 7, 2020 07:00AM Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights
Jul 7, 2020 04:02PM Aclaris Therapeutics (ACRS) Submits IND for ATI-1777 for the Treatment of Moderate to Severe Atopic Dermatitis
Jul 7, 2020 04:01PM Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical “Soft” JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
Jun 17, 2020 07:04AM Aclaris Therapeutics (ACRS) announces FDA has allowed investigational new drug application to evaluate ATI-450, its oral investigational MK2 inhibitor compound, in hospitalized patients with COVID-19
Jun 17, 2020 07:01AM Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19
Jun 3, 2020 07:03AM Aclaris Therapeutics (ACRS) Reports Publication of Abstract of Phase 1 Clinical Trial Results for ATI-450
Jun 3, 2020 07:00AM Aclaris Therapeutics Announces Publication of an Abstract of the Phase 1 Clinical Trial Results for ATI-450, an Investigational Compound, at the EULAR 2020 E-Congress
May 26, 2020 04:01PM Aclaris Therapeutics to Present at the Jefferies Virtual Healthcare Conference
May 7, 2020 04:01PM Aclaris Therapeutics Reports First Quarter 2020 Financial Results and Provides R&D and Business Highlights
Mar 31, 2020 04:01PM Aclaris Therapeutics Secures $11 Million Term Loan Facility
Feb 25, 2020 04:01PM Aclaris Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides R&D and Business Highlights
Feb 19, 2020 05:00PM Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
Feb 10, 2020 07:00AM Aclaris Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference
Jan 9, 2020 04:28PM Aclaris Therapeutics (ACRS) Reports Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450
Jan 9, 2020 04:27PM Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor
Jan 8, 2020 08:06AM Aclaris Therapeutics (ACRS) Names Vincent Milano to Board
Jan 8, 2020 08:00AM Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors
Nov 12, 2019 04:01PM Aclaris Therapeutics to Present at Upcoming Investor Conferences
Nov 7, 2019 04:01PM Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs
View Older Stories